NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · USA
Prestige Consumer Healthcare Inc is a mid cap company (market value between $2 billion and $10 billion) in the Drug Manufacturers - Specialty & Generic industry.
Prestige Consumer Healthcare develops, manufactures and distributes over-the-counter health and personal care products sold through mass merchandisers, pharmacies, food stores, dollar retailers, convenience stores, club outlets and e-commerce. The company operates across North America and selected international markets. Its portfolio includes established brands such as Monistat, Gaviscon, Dramamine and Chloraseptic.
From its FY2026 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Prestige Consumer Healthcare Inc stock.
Undervalued: intrinsic value $87.07 per share, market price $48.22, margin of safety 44.6% (as of 2026-11-17).
Discounting its cash flows at 6.8% (average of 3 methods) values the shares at $87.07; the price of $48.22 is 45% below that value, and 84% of that value comes from beyond year five.
17 more funds hold it; the full list is part of the paid plan.
All 82 Drug Manufacturers - Specialty & Generic stocks
1 more in this industry show a wider margin of safety.
PBH is undervalued (as of the 2026-11-17 close). Discounting its cash flows at 6.8% (average of 3 methods) values the shares at $87.07; the price of $48.22 is 45% below that value, and 84% of that value comes from beyond year five.
$87.07 per share (as of the 2026-11-17 close), against a market price of $48.22. That is a margin of safety of 44.6%. The value is the average of the 3 valuation methods that apply to this company, recomputed every night after the US close.